WHERE ARE YOU?

Concept Pre-Sub Submission prep Newly cleared Raising Postmarket & security

THE TAPE

Elucid raises $55M Series D with FFR-CT 510(k) under FDA review Enovis to buy eCential Robotics for 155 million euros FDA authorizes Vitestro's Aletta, the first autonomous blood-drawing robot, five months after a $70M Series B Renata Medical raises $25M Series D to scale the Minima pediatric stent FDA opens a docket on how to regulate generative AI devices FDA clears Jupiter Endovascular's Vertex thrombectomy system for pulmonary embolism in 89 days FDA clears Wandercraft's Eve, the first self-balancing exoskeleton for home use Meduloc raises $4M Series B to start alpha launch of its nitinol fracture implant FDA sets FY2027 device user fees: $28,653 for a 510(k), $13,785 to register Elucid raises $55M Series D with FFR-CT 510(k) under FDA review Enovis to buy eCential Robotics for 155 million euros FDA authorizes Vitestro's Aletta, the first autonomous blood-drawing robot, five months after a $70M Series B Renata Medical raises $25M Series D to scale the Minima pediatric stent FDA opens a docket on how to regulate generative AI devices FDA clears Jupiter Endovascular's Vertex thrombectomy system for pulmonary embolism in 89 days FDA clears Wandercraft's Eve, the first self-balancing exoskeleton for home use Meduloc raises $4M Series B to start alpha launch of its nitinol fracture implant FDA sets FY2027 device user fees: $28,653 for a 510(k), $13,785 to register

The Tracker / July 2026 / K253651

510(k) cleared

Revi System

Bluewind Medical , Ltd. · Jul 28, 2026 · K253651

FDA cleared the Revi System from Bluewind Medical , Ltd. on Jul 28, 2026 under K253651, a traditional 510(k). The device falls under product code QXM, Implanted Tibial Electrical Urinary Continence Device, regulated at 21 CFR 876.5305 as a Class 2 device. The review panel was Gastroenterology, Urology.

FDA logged the submission as received on Nov 20, 2025. The decision came 250 days later, longer than the 90 FDA-day review goal, which usually means at least one additional information request.

Bluewind Medical , Ltd. has one other decision in the tracker over the last 12 months: K252391 (Revi System).

Questions & Answers

What did FDA clear under K253651?

K253651 is the FDA 510(k) for Revi System, submitted by Bluewind Medical , Ltd.. FDA's decision date was Jul 28, 2026, under product code QXM (Implanted Tibial Electrical Urinary Continence Device).

Who makes the Revi System?

Bluewind Medical , Ltd., based in Herzliya, is the applicant of record for K253651.

How long did the K253651 review take?

FDA received the submission on Nov 20, 2025 and issued its decision on Jul 28, 2026, 250 days later.

← All decisions in July 2026

Sources